Letter to the Editor Regarding Management of Adult Patients with COVID-19 Outside Intensive Care Units: Guidelines from the Italian Society of Anti-Infective Therapy (SITA) and the Italian Society of Pulmonology (SIP)

Tommaso Manciulli; Michele Spinicci; Alessandro Bartoloni; Lorenzo Zammarchi

doi:10.1007/s40121-021-00565-w

Letter to the Editor Regarding Management of Adult Patients with COVID-19 Outside Intensive Care Units: Guidelines from the Italian Society of Anti-Infective Therapy (SITA) and the Italian Society of Pulmonology (SIP)

Infect Dis Ther. 2022 Feb;11(1):629-633. doi: 10.1007/s40121-021-00565-w. Epub 2021 Dec 10.

Authors

Tommaso Manciulli¹, Michele Spinicci¹, Alessandro Bartoloni¹, Lorenzo Zammarchi²

Affiliations

¹ Department of Experimental and Clinical Medicine, University of Florence, Largo Brambilla 3, Florence, Italy.
² Department of Experimental and Clinical Medicine, University of Florence, Largo Brambilla 3, Florence, Italy. lorenzo.zammarchi@unifi.it.

Abstract

Recently, the Italian Society of Anti-Infective Therapy (SITA) and the Italian Society of Pulmonology (SIP) published guidelines on the management of inpatients with COVID-19. The guidelines do not recommend the use of monoclonal antibodies (mAbs) in inpatients, pending results from clinical trials. However, recently the Italian Drug Agency (AIFA) has allowed for the use of casirivimab/imdevimab at higher doses in hospitalized seronegative patients with COVID-19. Furthermore, several other therapeutic options based on mAbs are about to become available for outpatients. Here we provide a brief summary of the future possibilities and summarize existing data.

Keywords: Anti-viral therapy; COVID-19; Monoclonal antibodies; SARS-CoV-2; Seronegative.

Publication types

Letter